2012 Annual Meeting

The following presentations were given during the 2012 NABP Annual Meeting, May 19-22, 2012, in Philadelphia, PA.

ONDCP – National Drug Plan to Combat Prescription Drug Abuse

During this special pre-meeting continuing pharmacy education (CPE) session, a representative from ONDCP will provide attendees with the most up-to-date information regarding how they coordinate all aspects of federal drug control programs and implement the President’s National Drug Control Strategy as it relates to combating the prescription drug abuse epidemic that is sweeping our nation.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  1. Explain how the current prescription drug abuse epidemic is affecting the nation.
  2. Describe the National Drug Control Strategy.
  3. Explain how the director of the Office of National Drug Control Policy (ONDCP) coordinates federal drug control programs.

Where Have All the Drugs Gone? – Who’s Responsible for Drug Shortages and Quotas?

It seems as if every day the drug products shortage notification list grows longer and increasingly includes controlled substances. During this joint CPE session, meeting attendees will hear from a DEA expert about how quotas are determined and enforced. An ASHP representative will also be on hand to provide the Association’s perspective on other causes including quality assurance and production capacity and present potential solutions.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  1. Describe how Drug Enforcement Administration (DEA) sets quotas for active pharmaceutical ingredients for controlled substances.
  2. Explain the process of how and when quotas are re-evaluated.
  3. Describe other causes of drug shortages including quality assurance and production capacity issues.

NABP/USP Breakfast

The NABP/USP Breakfast, sponsored by the United States Pharmacopeial Convention (USP), is an opportunity for both organizations to discuss timely and relevant topics in the pharmacy profession. USP representatives discuss newly proposed and released USP quality standards of relevance to the boards of pharmacy.

  • Rick Schnatz, PharmD, Senior Scientific Liaison, Healthcare Quality Standards, United States Pharmacopeial Convention
  • Jeanne Sun, PharmD, Assistant Scientific Liaison, Healthcare Quality Standards, United States Pharmacopeial Convention
    Joint Presentation: 2012 NABP-USP Breakfast (PDF)

Advancing Online Drug Safety: How Public-Private Partnerships Thwart Illicit Online Drug Sales

Whether selling controlled substances without requiring a prescription or peddling counterfeit medications, there is no doubt that rogue Internet pharmacies continue to place the public health at risk and can be extremely difficult for regulators to police. During this joint CPE session, experts from various public and private sectors will provide meeting attendees ways in which partnerships can stop these illegal operations.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  1. Describe the risks involved with purchasing medications from a rogue Internet pharmacy.
  2. Explain how partners in this effort are educating patients about the risks of purchasing from rogue pharmacies.
  3. Explain why public and private sectors must collaborate to cease rogue Internet pharmacies from operating.

OIG, NPDB, and HIPDB – What Everyone Should Know

As questions still remain about the OIG Exclusion List and the NPDB and HIPDB reporting, meeting attendees will be provided with the information about how board disciplinary actions relate to the OIG Exclusion List during this CPE session geared toward executive officers and board members. Attendees will also learn about the NPDB and HIPDB reporting requirements and utilizing reporting agents.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  1. Describe the types of offenses that can place a licensee on the Office of Inspector General (OIG) Exclusion List.
  2. Explain how the Healthcare Integrity and Protection Data Bank (HIPDB) and the National Practitioner Data Bank (NPDB) are related to each other.
  3. Describe how a reporting agent can be utilized to satisfy NPDB and HIPDB reporting requirements.

CSI Philadelphia – How to Conduct a Pharmacy Investigation

Being savvy with the ins and outs of how to conduct a pharmacy investigation is of paramount importance to board compliance officers in their efforts to protect the public. During this CPE session geared toward compliance officers, attendees will learn from pharmacy inspectors, who are also police officers, how to go about conducting an official pharmacy investigation – from collecting evidence to interviewing respondents and witnesses to drafting reports and testifying at hearings.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  1. Explain the necessary steps in conducting a pharmacy investigation.
  2. Describe how to collect evidence during a pharmacy investigation.
  3. Describe how to conduct a thorough pharmacy investigation interview.

Freedom for Consumers or Freedom from Meth – Point-Counterpoint

As the ravages of methamphetamine abuse in our country continue to rise so does the level of debate about whether to schedule pseudoephedrine, the main meth precursor, as a controlled substance prescription medication. This joint CPE session will delve into the issues including the pros and cons of various methods that decrease abuse and what is the best balanced solution for the future.

Learning Objectives:

At the conclusion of this session, participants will be able to:

  1. Explain the importance of tightening regulations so that pseudoephedrine cannot be used to manufacture methamphetamine.
  2. Describe the drawbacks for consumers if they are unable to purchase pseudoephedrine over-the-counter.
  3. Describe methods to decrease illegal purchases of pseudoephedrine.
RSS

Recent News

More Newsroom Headlines »